Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak
- PDF / 209,047 Bytes
- 7 Pages / 547.087 x 737.008 pts Page_size
- 34 Downloads / 202 Views
(0123456789().,-volV) ( 01234567 89().,-volV)
REVIEW
Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak Massimo Nicolo` . Lorenzo Ferro Desideri . Matteo Bassetti . Carlo Enrico Traverso
Received: 27 May 2020 / Accepted: 5 September 2020 Ó The Author(s) 2020
Abstract Purpose The current coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization a global pandemic. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been largely adopted in the clinical setting for the management of SARS-CoV-2 infection; however, their known retinal toxicity has raised some safety concerns, especially considering the higher-dosage employed for COVID19 patients as compared with their suggested posology for their usual indications, including systemic lupus erythematosus and other rheumatic diseases.In this review, we will discuss the optimal dosages recommended for COVID-19 patients when treated with HCQ and CQ.
M. Nicolo` (&) L. Ferro Desideri C. E. Traverso IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy e-mail: [email protected] M. Nicolo` L. Ferro Desideri C. E. Traverso Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy
Methods A comprehensive literature search was performed in PubMed, Cochrane library, Embase and Scopus, by using the following search terms: ‘‘chloroquine retinal toxicity’’ and ‘‘hydroxychloroquine retinal toxicity’’ alone or in combination with ‘‘coronavirus’’, ‘‘COVID-19’’, ‘‘ SARS-CoV-2 infection ’’ from inception to August 2020. Results Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern. For this reason, appropriate screening strategies, including telemedicine, should be developed in the near future. Conclusion A possible future clinical perspective for patients with COVID-19 treated with HCQ/CQ could reside in the multidisciplinary collaboration between ophthalmologists monitoring the risk of HCQ/CQrelated retinal toxicity and those physicians treating COVID-19 infection. Keywords Hydroxychloroquine Chloroquine Retina Retinal safety COVID-19 Coronavirus SARCoV-2
M. Nicolo` Macula Onlus Foundation, Genova, Italy
Introduction
M. Bassetti Infectious Diseases Clinic, Department of Health Sciences, University of Genova and Ospedale Policlinico San Martino- IRCCS Per L’Oncologia, Genova, Italy
The current coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization (WHO) a global pandemic in early March 2020 [1]. To
123
Int Ophthalmol
date, no specific therapy has been identified for treating COVID-19; however, beside antiviral drugs, chloroquine (CQ) and hydroxychloroquine (HCQ) have been employed for the management of SARSCoV-2 infection [2]. In this regard, HCQ and CQ belong to the class of synthetic antimalarial drugs, whic
Data Loading...
